The SNF2-related CBP activator protein (SrCap) is a potent activator of transcription mediated by CBP and CREB. We have previously demonstrated that the Adenovirus 2 DNA Binding Protein (DBP) binds to SrCap and inhibits the transcription mediated by the carboxyl-terminal region of SrCap (amino acids 1275-2971). We report here that DBP inhibits the ability of full-length SrCap (1-2971) to activate transcription mediated by Gal-CREB and Gal-CBP. In addition, DBP also inhibits the ability of SrCap to enhance Protein Kinase A (PKA) activated transcription of the enkaphalin promoter. DBP was found to dramatically inhibit transcription of a mammalian two-hybrid system that was dependent on the interaction of SrCap and CBP binding domains. We also found that DBP has no effect on transcription mediated by a transcriptional activator that is not related to SrCap, indicating that our reported transcriptional inhibition is specific for SrCap and not due to nonspecific effects of DBP's DNA binding activity on the CAT reporter plasmid. Taken together, these results suggest a model in which DBP inhibits cellular transcription mediated by the interaction between SrCap and CBP.
Introduction
The cyclic-AMP responsive element-binding protein (CREB) regulates the transcription of several genes (Daniel et al., 1998; Montminy, 1997) . CREB targets these genes by binding to the sequence-specific cyclic-AMP responsive element (CRE) found in many promoters. An increased level of cAMP stimulates gene expression from CRE-containing promoters. The increase in transcription is largely due to phosphorylation of CREB at serine 133 by cAMPactivated Protein Kinase A (PKA) (Shaywitz and Greenberg, 1999) . Phosphorylation of CREB by PKA facilitates the association of CREB with the CREB-binding protein, CBP (Chrivia et al., 1993; Kwok et al., 1994) . CBP is critical for CREB-mediated transcriptional activation (Korzus et al., 1998) . Studies to determine what regions within CBP were important for it to function as a CREB coactivator led to the identification of a transcriptional activation domain defined within amino acids 227-460 (Swope et al., 1996) , shown in Fig. 1A . This region overlaps a region of CBP (amino acids 1-450) that has been shown to interact with the Adenovirus (Ad) E1A proteins and is distinct from the CREB binding domain within CBP located within amino acids 586 -666 (Radhakrishnan et al., 1997) .
Our previous studies utilizing CBP amino acids 227-460 as bait in a yeast two-hybrid screen led to the identification of a novel gene product that binds to CBP. This protein shares structural features with proteins in the SNF2 protein family, most notably seven regions that collectively comprise a functional ATPase domain (Johnston et al., 1999 ) (see Fig. 1B ). The SNF2 protein family are involved in chromatin remodeling, DNA repair, and transcriptional regulation (Sudarsanam and Winston, 2000) . Since we have demonstrated that this protein can enhance the ability of CBP to activate transcription, we have called it SrCap (SNF2-related CBP activator protein). In a more recent study, we have demonstrated that SrCap serves as a coactivator for the transcription factor CREB, which is known to interact with CBP (Johnston et al., 1999; Monroy et al., 2001) .
Among a wide variety of transcription factors that physically interact with CBP at several separate and defined regions (Daniel et al., 1998; Goldman et al., 1997; Montminy, 1997) , both SrCap and the E1A proteins were shown to bind to overlapping regions on CBP (see Fig. 1A ) (Johnston et al., 1999; Kurokawa et al., 1998) . The binding of the E1A proteins to CBP and to the closely related protein family member, p300, are both strongly implicated in the ability of E1A to activate cell growth and to repress differentiation and tissue-specific transcription (Moran, 1994) . We have demonstrated that wild-type E1A, but not an E1A mutant unable to bind CBP/p300, inhibits transcription in a mammalian two-hybrid CAT assay that is dependent on the interaction between the SrCap and CBP binding regions. The apparent competitive inhibition of the binding interaction between SrCap and CBP by E1A in this system represents a possible mechanism that may contribute to E1A-mediated transcriptional repression (Johnston et al., 1999) .
In the course of these studies on the effect of adenovirus gene expression on SrCap, we found that the Ad 2 DNA Binding Protein (DBP) binds to SrCap and strongly inhibits SrCap-mediated transcriptional activity . DBP is a 529 amino acid protein that binds to both singleand double-stranded DNA and RNA (Cleghon and Klessig, 1986; Neale and Kitchingman, 1990) . In vitro studies have shown that DBP can function in the initiation and elongation phases of DNA replication, suggesting an in vivo model that DBP functions to unwind double-strand viral DNA by multimerizing along the displaced single-stranded viral DNA (Shenk, 1996) . DBP is also tightly involved in other essential functions important in the adenovirus life cycle, including viral RNA stability (Cleghon et al., 1989) , virus assembly (Nicolas et al., 1983) , determination of virus host range (Anderson et al., 1983) , and transformation (Rice et al., 1987) .
In addition, DBP is implicated in transcriptional regulation. With the exception of the adenovirus E4 promoter, which is slightly inhibited by DBP, DBP generally activates transcription from viral promoters. These include the adenovirus E1A, E2A, and major late promoters, and the adeno-associated virus P5 promoter (Chang and Shenk, 1990) . In the major late promoter and P5 promoter, DBP increases transcription by enhancing the binding affinity of a transcription factor (termed upstream stimulatory factor 1 (USF1), and also known as the major late transcription factor (MLTF)), to its associated binding site present in both promoters (Zijderveld et al., 1994) . DBP also enhances the ability of the transcription/replication factor, NF1, to bind to its associated DNA recognition site in the adenovirus origin of replication (Stuiver and van der Vliet, 1990) . This ability of DBP to enhance the affinity of transcription factors for their cognate recognition sites may represent a mechanism of DBP-mediated activation of transcription. While DBP has been shown to activate several viral promoters, the effects of DBP on cellular promoters have not been reported. This is an interesting question because, similar to the E1A's abilities to both activate and repress gene expression (Moran and Mathews, 1987) , DBP may also contribute to a reduction of at least a subset of host cell gene expression while activating viral gene expression.
Given our previous observation that DBP binds to SrCap and strongly inhibits SrCap-mediated transcription , and considering that SrCap is a coactivator of CBP (Johnston et al., 1999; Monroy et al., 2001) , we tested whether DBP is able to influence transcription of the CBP and CREB-responsive cellular enkephalin promoter.
Results and discussion

DBP inhibits SrCap-dependent activation of the PKA/CREB-activated enkephalin promoter
To test whether DBP has any effect on PKA-activated CREB-mediated transcription, we transfected CHO cells as described previously ) with a CAT reporter construct containing the enkephalin promoter, pEnk12-CAT. This promoter contains two cyclic-AMP responsive elements and has been used by others to study CREBmediated transcription (Huggenvik et al., 1991) . Also transfected were one or more of the following plasmids: pRc/ RSV-CREB, a plasmid that expresses the CREB protein (Walton et al., 1992) ; pPKA, a plasmid that expresses the catalytic subunit of protein kinase; pSrCap(1-2971); and pcDNA-DBP. As shown in Fig. 2 , cotransfection of plas- mids expressing PKA and CREB, or PKA and CREB with SrCap, activated transcription 4-and 12-fold, respectively. The PKA-mediated enhancement of CREB-mediated transcription is presumably due to PKA phosphorylation of CREB at residue 133, which facilitates the association of phospho-CREB with endogenous CBP to activate transcription. Endogenous SrCap probably also participates in this transcriptional activation, given that exogenously expressed SrCap has a strong activation effect. When a plasmid expressing DBP was cotransfected with plasmids expressing PKA and CREB with SrCap, the observed transcriptional activation was reduced from 12-to 7.3-fold. Thus, DBP inhibits the effect of exogenously expressed SrCap on PKA-CREB-CBP-mediated transcription in the context of a cellular promoter. In the absence of exogenously expressed SrCap, DBP reduced PKA and CREB-mediated activation from 4-to 2.4-fold. Presumably, this represents DBP interference with endogenous SrCap. It appears that DBP plays a role in both the activation of virus genes and the inhibition of host cell genes. Similar results were obtained when these assays were performed in HeLa cells (data not shown).
To address the possibility that DBP-mediated inhibition of enkephalin promoter activity is not due to promoterspecific effects, such as DBP interaction with a PKA-stimulated transcription factor other than CREB, we asked whether DBP could also inhibit the transcription activity induced by a Gal-CREB fusion protein from pGal-CAT, a CAT reporter plasmid that contains a Gal4 responsive element.
DBP inhibits SrCap-activation of Gal-CREB-mediated transcription
CHO cells were transfected with the reporter plasmid pGal-CAT, plus pGal-CREB, a plasmid that expresses the CREB protein fused with the Gal4 DNA-binding domain (Kwok et al., 1994) . The transfected plasmid set variously included pPKA, pSrCap(1-2971), and pcDNA-DBP. As shown in Fig. 3 , PKA enhanced Gal-CREB-mediated transcription 4.7-fold. The addition of full-length SrCap further activated PKA-enhanced Gal-CREB-mediated transcription to 7.5-fold. These results are consistent with those previously reported . However, in the presence of DBP, PKA-enhanced Gal-CREB-mediated transcription was reduced from 4.7-to 1.9-fold. Activity in the presence of SrCap was reduced from 7.5-to 5.2-fold. These data suggest that DBP-mediated inhibition is not specific to the promoter element, but is an effect on the transcription complex containing CREB, CBP, and SrCap.
DBP inhibits SrCap-activated Gal-CBP-mediated transcription
To test the hypothesis that DBP inhibits transcription via impairment of the CBP-SrCap interaction, we tested Fig. 3 . DBP inhibits SrCap-activation of Gal-CREB-mediated transcription. CHO cells were transfected as indicated with 100 ng of pGal-CAT reporter plasmid, 100 ng of a plasmid encoding a Gal-CREB chimera (pGal-CREB), 25 ng of a plasmid encoding the catalytic subunit of PKA (pPKA) as indicated, 2000 ng of a plasmid encoding SrCap (pSrCap), and 250 ng of a plasmid encoding Adenovirus DBP (pcDNA-DBP) as indicated. The relative CAT enzymatic activity was determined by dividing the CAT enzymatic activity of each sample by the transcriptional activity induced by the Gal-CREB chimera (which was assigned a relative value of 1). Values represent the means Ϯ SE from at least two separate experiments in which each sample was assayed in triplicate. Fig. 2 . DBP inhibits SrCap-activation of the PKA/CREB-activated CREcontaining promoter. CHO cells were transfected as indicated with 100 ng of pEnk12-CAT reporter plasmid, 100 ng of a plasmid encoding CREB (pCREB), 50 ng of a plasmid encoding the catalytic subunit of PKA (pPKA), 2000 ng of a plasmid encoding full-length (FL) SrCap (pSrCap(FL)), and 250 ng of a plasmid encoding Adenovirus DBP (pcDNA-DBP). The relative CAT enzymatic activity was determined by dividing the CAT enzymatic activity of each sample by the transcriptional activity induced by the pEnk 12-CAT (which was assigned a relative value of 1). Values represent the means Ϯ SE from at least two separate experiments in which each sample was assayed in triplicate.
whether DBP could inhibit the ability of SrCap to activate transcription of a Gal-CBP chimera in a system that does not require CREB. CHO cells were transfected with the pGal-CAT reporter plasmid plus pGal-CBP, which expresses full-length CBP fused with the Gal4-DNA binding domain (the plasmids are described in Monroy et al. 2001) . One set of transfected cells also received pSrCap(1-2971). Transcription activity in this system was measured in the presence and absence of pcDNA-DBP. In Fig. 4 , we observed that DBP expression reduced the ability of the Gal-CBP chimera to activate transcription by 30%. A similar reduction of activity was observed in the SrCap-transfected cells. These results are consistent with the suggestion that DBP functions by disrupting the CBP-SrCap interaction. To test this hypothesis, we asked directly whether DBP could functionally inhibit the interaction between CBP and SrCap.
DBP disrupts the interaction between SrCap and CBP
To test whether DBP can functionally disrupt the SrCap-CBP interaction, we used a mammalian two-hybrid CATreporter system designed to function through the SrCap and CBP interaction domains (Johnston et al., 1999) . This twohybrid system was originally used to demonstrate that E1A could disrupt the CBP-SrCap functional interaction (Johnson et al., 1999) . CHO cells were transfected with the pGal-CAT reporter plasmid, plus pGal-CBP (280 -460), which expresses the SrCap-binding domain of CBP, plus pVP16-SrCap (1380 -1729), which contains the CBP-binding domain of SrCap (Johnston et al., 1999) . The transfection system was tested, with or without pcDNA-DBP. As shown in Fig. 5 , VP16-SrCap (1380 -1729) activated transcription mediated by pGal-CBP (280 -460) 26-fold. Addition of DBP blocked this activity in a dose-dependent manner, indicating that DBP disrupts the interaction of SrCap and CBP. The ability of DBP to slightly inhibit transcription in the absence of VP16-SrCap (1380 -1729) is presumably due to a functional disruption of the interaction between endogenous SrCap and Gal-CBP (280 -460).
To distinguish between the possibilities that the inhibition is due to a direct effect of DBP interacting with SrCap or some aberrant interaction of DBP with the Gal4 portion of the fusion protein or a direct interaction of DBP's DNAbinding activity with the CAT reporter plasmid, we tested whether DBP could inhibit a transcription factor that was unrelated to SrCap.
DBP has no effect on the transcriptional activity of a transcriptional activator that is not related to SrCap
To determine whether DBP affected the transcription activity of a known transcriptional activator that is not related to the SrCap protein, we tested whether DBP could regulate the FOXC1 transcriptional activator. FOXC1 is a member of the Forkhead Box family of transcription factors that share a 110 amino acid DNA binding domain that is located roughly within amino acids 78 -188. Computer analysis FOXC1 and SrCap amino acid sequences revealed that these proteins were not related. Analysis of various fragments of FOXC1, expressed as Gal4 fusion proteins, Fig. 5 . DBP disrupts the binding interaction of SrCap/CBP. CHO cells were transfected as indicated with 100 ng of pGal-CAT reporter plasmid, 200 ng of a plasmid encoding Gal-CBP-(280 -460) chimera (pGal-CBP(280 -460)), 200 ng of a plasmid encoding VP16-clone 11 chimera (pVP16-SrCap), and the indicated amounts of a plasmid encoding Adenovirus DBP (pcDNA-DBP). The relative CAT enzymatic activity was determined by dividing the CAT enzymatic activity of each sample by the transcriptional activity induced by the Gal-CAT (which was assigned a relative value of 1). Values represent the means Ϯ SE from at least three separate experiments in which each sample was assayed in triplicate. Fig. 4 . DBP inhibits SrCap-activated Gal-CBP-mediated transcription. CHO cells were transfected as indicated with 100 ng of pGal-CAT reporter plasmid, 100 ng of a plasmid encoding a Gal-CBP chimera (pGal-CBP), 1000 ng of a plasmid encoding SrCap (pSrCap), and 250 ng of a plasmid encoding Adenovirus DBP (pcDNA-DBP) as indicated. The relative CAT enzymatic activity was determined by dividing the CAT enzymatic activity of each sample by the transcriptional activity induced by the Gal-CBP chimera (which was assigned a relative value of 1). Values represent the means Ϯ SE from at least three separate experiments in which each sample was assayed in triplicate.
has mapped a strong transcriptional activation domain to carboxyl-terminal amino acids 435-553 (Berry et al., 2002) . We have independently constructed a series of Gal4 -FOXC1 fusion protein and determined their abilities to activate transcription from a GRE-containing CAT reporter plasmid (V. Tarakanova and W.S.M. Wold, unpublished results). We determined that one of these constructs, pGal-FOXC1(amino acids 283-553), induced relative CAT activity that was very similar to the amount that was induced by Gal-SrCap (see Fig. 6 ). In the presence of a moderate amount (150 ng) of the DBP expressing plasmid, the relative CAT activity induced by Gal-SrCap was dramatically reduced to 24%. However, in the presence of a large amount (500 ng) of the DBP-expressing plasmid the relative CAT activity induced by Gal-FOXC1 was undiminished. This result is consistent with our result that DBP also had no significant inhibitory effect on another SrCap-independent Gal construct, namely Gal-VP16 . Since the Gal portions of the Gal-FOXC1 and Gal-SrCap fusion proteins are identical, it suggests that DBP's transcriptional inhibition of Gal-SrCap-induced CAT activity is not acting through an aberrant interaction between DBP and the Gal4 portion of the Gal-SrCap fusion protein. Rather, this data do indicate that DBP's inhibition of Gal-SrCap-induced CAT activity is specific for the SrCap portion of the Gal-SrCap fusion protein. In addition, since the CAT reporter plasmid is the same in these assays, it suggests that DBP's DNA binding assay does not inhibit the CAT activity induced by Gal-SrCap through a direct interaction with the CAT reporter plasmid.
While DBP is known to be cytotoxic (Klessig et al., 1984) , we do not observe cytopathic effects in these shortterm CAT assays. More interestingly, since we observe DBP inhibition of SrCap-mediated transcription and not inhibition of SrCap-independent transcription, it would suggest that DBP preferentially targets cellular proteins, such as SrCap, while in the presence of a vast excess of cellular nucleic acid targets.
These data presented above suggest that, analogous to the E1A proteins, which induce a portion of their transcriptional repression activities through their interaction with CBP and/or p300, DBP can inhibit transcription through its interaction with SrCap. One apparent consequence of the disruption of the SrCap-CBP interaction by DBP is that PKA-activated CREB-mediated transcription is repressed. Whether DBP has a similar role at all or a subset of host promoters regulated by cAMP in the context of an Adenoviral infection is currently under investigation.
These findings suggest a model in which Adenovirus expresses two viral gene products, DBP and E1A, that disrupt the same cellular protein complex by targeting SrCap and CBP, respectively (see Fig. 7 ). The reason Adenovirus would redundantly target the SrCap-CBP interaction and how this benefits the virus is not known. Since both DBP and E1A can functionally and independently inhibit transcription in the SrCap-CBP mammalian two-hybrid assay, it suggests that functional disruption of this cellular interaction may be an important target for Adenovirusinduced host cell regulation. We propose that the functional disruption is due to a physical disruption of the SrCap-CBP interaction. In this model, the binding of DBP to SrCap disrupts the SrCap-CBP interaction and makes CBP more accessible to E1A. We also speculate that this could enable E1A to sequester CBP (and p300) to form a complex with Fig. 6 . DBP specifically inhibits SrCap-mediated transcription. CHO cells were transfected with the reporter plasmid pGal-CAT (100 ng), either pGal-SrCap (500 ng) or pGal-FOXC1 (200 ng), with or without pcDNA-DBP (150 ng in the pGal-SrCap set or 500 ng in the pGal-FOXC1 set), as indicated. Transfections were normalized to equal picomolar amounts of plasmid DNAs (using decreasing amounts of empty vector pcDNA) and to total amount of DNA (using salmon sperm DNA). Values are the means Ϯ SE (error bars) from two separate experiments in which each point was performed in triplicate.
Rb. This resulting complex formed between E1A, CBP (or p300), and Rb has been shown to be essential for the abilities of E1A proteins to fully activate the cell cycle (Wang et al., 1995) . In addition, in the E1A/CBP/p300/Rb complex, the intrinsic CBP/p300 acetyltransferase activities have been shown to acetylate Rb and regulate the ability of Rb to form a protein-protein interaction with MDM2 (Chan et al., 2001 ). In addition, since SrCap could no longer coactivate CBP-mediated transcription, a portion of CBPmediated transcription of CBP-regulated cellular genes would be repressed. Taken together, these results suggest an intriguing DBP-mediated mechanism of host cell transcriptional regulation.
